The role of uric acid in Parkinson’s disease: a UK brain bank pathology-validated case–control study

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Neurological Sciences

• Publication date

  2025-03-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10072-025-08112-yPMID 40113639
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Are we entering the 'Tau-lemaic' era of Parkinson's disease?

  2024cited by this paper
• Smoking exposure and Parkinson's disease: A UK Brain Bank pathology-validated case-control study.

  2024cited by this paper
• Uric acid: The role in the pathophysiology and the prediction in the diagnosis of Parkinson's disease: A Turkish-based study.

  2022cited by this paper
• Association between gout and the development of Parkinson’s disease: a systematic review and meta-analysis

  2022cited by this paper
• Uric Acid in Parkinson′s Disease: What Is the Connection?

  2022influential reference
• Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease

  2022cited by this paper
• The glucocerebrosidase mutations and uric acid levels in Parkinson’s disease: A 3-years investigation of a potential biomarker”

  2022cited by this paper
• Effect of Urate-Elevating Inosine on Progression of Early Parkinson Disease.

  2022cited by this paper
• Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial.

  2021cited by this paper
• Mendelian Randomisation Finds No Causal Association between Urate and Parkinson's Disease Progression

  2021cited by this paper
• Improved Parkinsons disease motor score in a single-arm open-label trial of febuxostat and inosine

  2020cited by this paper
• Environmental and genetic risk factors for Parkinson's disease

  2020cited by this paper
• What Is the Biological Function of Uric Acid? An Antioxidant for Neural Protection or a Biomarker for Cell Death

  2019cited by this paper
• Serum uric acid levels in patients with Parkinson’s disease: A meta-analysis

  2017influential reference
• Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis

  2016cited by this paper
• Accuracy of clinical diagnosis of Parkinson disease

  2016cited by this paper
• Association between serum uric acid and motor subtypes of Parkinson's disease.

  2015cited by this paper
• Serum Uric Acid and Nigral Iron Deposition in Parkinson’s Disease: A Pilot Study

  2014cited by this paper
• Lower Serum Bilirubin and Uric Acid Concentrations in Patients with Parkinson’s Disease in China

  2014cited by this paper
• Epidemiology and Clinical Diagnosis of Parkinson Disease.

  2013influential reference
• Serum Urate and the Risk of Parkinson's Disease: Results From a Meta-Analysis

  2013influential reference
• Genetic variability related to serum uric acid concentration and risk of Parkinson's disease

  2013cited by this paper
• Low serum uric acid concentration in Parkinson's disease in southern Spain

  2013cited by this paper
• Association of serum uric acid levels with the progression of Parkinson's disease in Chinese patients.

  2012cited by this paper
• Lower serum UA levels in Parkinson's disease patients in the Chinese population.

  2012cited by this paper
• Serological Profiles of Urate, Paraoxonase-1, Ferritin and Lipid in Parkinson’s Disease: Changes Linked to Disease Progression

  2011cited by this paper
• Serum and Cerebrospinal Fluid Uric Acid Levels in Lewy Body Disorders: Associations with Disease Occurrence and Amyloid-β Pathway

  2011cited by this paper
• Uric acid and cognition in Parkinson's disease: a follow-up study.

  2011cited by this paper
• The Risk of Parkinson Disease Associated with Urate in a Community-Based Cohort of Older Adults

  2011cited by this paper
• Plasma urate and Parkinson's disease in women.

  2010cited by this paper
• Prevalence and clinical features of LRRK2 mutations in patients with Parkinson’s disease in southern Spain

  2009cited by this paper
• Urate as a predictor of the rate of clinical decline in Parkinson disease.

  2009cited by this paper
• Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration.

  2009cited by this paper
• Serum urate as a predictor of clinical and radiographic progression in Parkinson disease.

  2008cited by this paper
• Low plasma uric acid level in Parkinson's disease

  2007cited by this paper
• Plasma urate and risk of Parkinson's disease.

  2007cited by this paper
• Serum uric acid levels and the risk of Parkinson disease

  2005cited by this paper
• Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease.

  1996cited by this paper
• Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group.

  1996cited by this paper
• Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa

  1996cited by this paper
• Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis.

  1981cited by this paper
• American Journal of Epidemiology Original Contribution Plasma Urate and Parkinson's Disease in the Atherosclerosis Risk in Communities (aric) Study

  year unknowncited by this paper

• AI Video Analysis in Parkinson’s Disease: A Systematic Review of the Most Accurate Computer Vision Tools for Diagnosis, Symptom Monitoring, and Therapy Management

  2025cites this paper
• Computer Vision Analysis for Objective Motor Assessment in Parkinson's Disease: A Retrospective Study.

  2025cites this paper